Heart Failure and Pulmonary Hypertension

Heart Failure Clinics

Volumn 6, Issue 2, 2010, Pages 215-222

  Shin, Jordan T ^a   Semigran, Marc J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

BMPR2; Heart failure; Nitric oxide; PDE5; Pulmonary hypertension

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; PHOSPHODIESTERASE V; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTERIAL WALL THICKENING; BIOLOGY; CELL PROLIFERATION; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOWN REGULATION; DYSPNEA; ECHOCARDIOGRAPHY; EDEMA; FATIGUE; GENE MUTATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PALPITATION; HISTOLOGY; HOMOZYGOSITY; HUMAN; HYPOXEMIA; IDIOPATHIC DISEASE; INTIMA; LUNG BLOOD VESSEL; LUNG PRESSURE; PATHOGENESIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RENDU OSLER WEBER DISEASE; REVIEW; SIGNAL TRANSDUCTION; SYNCOPE; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; THROMBOSIS;

BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MUTATION; NITRIC OXIDE; PROGNOSIS; SIGNAL TRANSDUCTION; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 77950218243     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2009.11.007     Document Type: Review

References (54)

1. Lloyd-Jones D.M., Larson M.G., Leip E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106 (2002) 3068
2. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119 (2009) 480
3. Ghio S., Gavazzi A., Campana C., et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37 (2001) 183
4. Gavazzi A., Ghio S., Scelsi L., et al. Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension. Am Heart J 145 (2003) 310
5. Simonneau G., Galie N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 (2004) 5S
6. Rubin L.J. Primary pulmonary hypertension. N Engl J Med 336 (1997) 111
7. Farber H.W., and Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 351 (2004) 1655
8. Fishman A.P. Clinical classification of pulmonary hypertension. Clin Chest Med 22 (2001) 385
9. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107 (1987) 216
10. Leuchte H.H., Holzapfel M., Baumgartner R.A., et al. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest 128 (2005) 2368
11. Runo J.R., and Loyd J.E. Primary pulmonary hypertension. Lancet 361 (2003) 1533
12. Rubin L.J. Primary pulmonary hypertension. Chest 104 (1993) 236
13. Rich S., and Rabinovitch M. Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation 118 (2008) 2190
14. Oudiz R.J. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 28 (2007) 233
15. Butler J., Chomsky D.B., and Wilson J.R. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol 34 (1999) 1802
16. Lam C.S., Roger V.L., Rodeheffer R.J., et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53 (2009) 1119
17. Di Salvo T.G., Mathier M., Semigran M.J., et al. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 25 (1995) 1143
18. Semigran M.J., Cockrill B.A., Kacmarek R., et al. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 24 (1994) 982
19. Koelling T.M., Kirmse M., Di Salvo T.G., et al. Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction. Am J Cardiol 81 (1998) 1494
20. Lewis G.D., Lachmann J., Camuso J., et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115 (2007) 59
21. Lewis G.D., Shah R., Shahzad K., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 116 (2007) 1555
22. Behling A., Rohde L.E., Colombo F.C., et al. Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 14 (2008) 189
23. Guazzi M., Samaja M., Arena R., et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 50 (2007) 2136
24. Szokodi I., Piuhola J., and Ruskoaho H. Endothelin receptor blockade and exacerbation of heart failure. Circulation 107 (2003) e211
25. Anand I., McMurray J., Cohn J.N., et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 347
26. Packer M., McMurray J., Massie B.M., et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 11 (2005) 12
27. Califf R.M., Adams K.F., McKenna W.J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 (1997) 44
28. Takimoto E., Champion H.C., Li M., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11 (2005) 214
29. Archer S., and Rich S. Primary pulmonary hypertension: a vascular biology and translational research "Work in progress. Circulation 102 (2000) 2781
30. Tuder R.M., Groves B., Badesch D.B., et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144 (1994) 275
31. Tuder R.M., Chacon M., Alger L., et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 195 (2001) 367
32. Lee S.D., Shroyer K.R., Markham N.E., et al. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 101 (1998) 927
33. Tuder R.M., Radisavljevic Z., Shroyer K.R., et al. Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Am J Respir Crit Care Med 158 (1998) 1999
34. Deng Z., Morse J.H., Slager S.L., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67 (2000) 737
35. Lane K.B., Machado R.D., Pauciulo M.W., et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 26 (2000) 81
36. Thomson J.R., Machado R.D., Pauciulo M.W., et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 37 (2000) 741
37. Machado R.D., Pauciulo M.W., Thomson J.R., et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68 (2001) 92
38. Newman J.H., Wheeler L., Lane K.B., et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 345 (2001) 319
39. McAllister K.A., Grogg K.M., Johnson D.W., et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8 (1994) 345
40. Johnson D.W., Berg J.N., Baldwin M.A., et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13 (1996) 189
41. Du L., Sullivan C.C., Chu D., et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 348 (2003) 500
42. Dorai H., Vukicevic S., and Sampath T.K. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 184 (2000) 37
43. Nakaoka T., Gonda K., Ogita T., et al. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest 100 (1997) 2824
44. Willette R.N., Gu J.L., Lysko P.G., et al. BMP-2 gene expression and effects on human vascular smooth muscle cells. J Vasc Res 36 (1999) 120
45. Miyazono K., Kusanagi K., and Inoue H. Divergence and convergence of TGF-beta/BMP signaling. J Cell Physiol 187 (2001) 265
46. Yamada M., Revelli J.P., Eichele G., et al. Expression of chick Tbx-2, Tbx-3, and Tbx-5 genes during early heart development: evidence for BMP2 induction of Tbx2. Dev Biol 228 (2000) 95
47. Brown III C.O., Chi X., Garcia-Gras E., et al. The cardiac determination factor, Nkx2-5, is activated by mutual cofactors GATA-4 and Smad1/4 via a novel upstream enhancer. J Biol Chem 279 (2004) 10659
48. Zhao G.Q. Consequences of knocking out BMP signaling in the mouse. Genesis 35 (2003) 43
49. Walters M.J., Wayman G.A., and Christian J.L. Bone morphogenetic protein function is required for terminal differentiation of the heart but not for early expression of cardiac marker genes. Mech Dev 100 (2001) 263
50. Yu P.B., Beppu H., Kawai N., et al. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J Biol Chem 280 (2005) 24443
51. Beppu H., Kawabata M., Hamamoto T., et al. BMP type II receptor is required for gastrulation and early development of mouse embryos. Dev Biol 221 (2000) 249
52. Beppu H., Ichinose F., Kawai N., et al. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol 287 (2004) L1241
53. Song Y., Jones J.E., Beppu H., et al. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 112 (2005) 553
54. West J., Fagan K., Steudel W., et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 94 (2004) 1109